Skip to content

MontiNefro

Active Private limited companyfounded 2012active for 13 yearsGagelstraat 3, 8200 BrugesKBO/BCE: BE 0501.826.728

Lifetime

13 annual accounts with figures on one time axis
peak of €530,936 in 2025
€530,936▲ 0.5%
peak of €372,932 in 2025
€372,932▲ 2.5%
peak of €1.6m in 2025
€1.6m▲ 7.0%
€326,958▲ 19.0%
peak of 0.3 FTE in 2015
-not published
Board2 names since 2021
1 director
Documentsfilings and deeds
31-07-2026on the last day
2025micro format
Dividend €266,380Debts from €274,661 to €326,958Cash from €1.5m to €579,259

Key points

from the 2025 annual accounts

Equity

€1.6m ▲ 7.0%
1.52024+0.4Profit-0.3Dividend1.62025

MontiNefro paid out €266,380 in dividends. That is 71% of the 2025 profit.

Filings

13 annual accounts since 2013
AprilJune31 JulyOctober201520202025

The last five annual accounts were filed 0 to 40 days before the end of the period.

Position in the sector

€372,932

Higher net result than 95% of companies in human health. Sector median €59,542 · 21,323 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 17,811 companies had the same profile as MontiNefro has now. Each dot stands for 45 companies, two years later.

96.5%
were still trading
3.2%
stopped another way
0.3%
went bankrupt
  • Small
  • 10 to 20 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,760 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 17,811 companies, not a prediction for MontiNefro. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • all the sharesdeed of 23-11-2023
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0501826728
Company renamed from DR. BARBARA VAN DEN BERGH to MontiNefro changes role from statutory manager to statutory director · resigns as statutory manager and successor · “Het inrichten van algemene diensten en een medisch secretariaat in het bijzonder die nuttig of nodig zijn voor…” (deed in Dutch) · Gazette deed
Registered office moved from Jabbeke to Sint-Andries The registered office moved from Ettelgemstraat 22, 8490 Jabbeke to Gagelstraat 3, 8200 Sint-Andries · General meeting of 13-08-2020 · Gazette deed
Director in office: (manager) Gazette deed
All 25 events

Comparable companies

same main activity, similar in size and age
Company
MontiNefro Bruges €2.0m €530,936 83.3% -
Dokter Jeroen Dockx MKA Zwevegem €1.9m €516,198 85.3% -
NEURALGO Bruges €1.8m €545,694 35.0% -
DR. MOTTRIE ALEXANDRE, UROLOOG Aalst €1.8m €494,936 93.4% -
DOKTER BART DE TROYER, UROLOOG Sint-Niklaas €1.8m €507,569 95.7% -
DR. LIESBETH LAUREYN Tessenderlo-Ham €1.8m €540,405 52.0% -
Dr. Nancy Verdonck Woluwe-Saint-Pierre €2.0m €577,741 93.3% 2.2

These companies have the same main activity as MontiNefro: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €1.8m and €2m, founded between 2011 and 2014.

Official details

Source: KBO
Status
Active since 07-12-2012Normal situation
Activity
Specialist medical practiceNACE 86220
Establishment unit
2.214.954.6168000 Bruges, since 01-01-2013
Financial year end
31 December
Peppol
Reachable since 17-10-2025
Company details

Annual accounts 2025

≈ €800,000estimated
€2.0m▲ 8.8%
Filing
Filed on 31-07-2026, on the last day of the filing period
Financials

Insights on MontiNefro

MontiNefro files the micro format. That format states no turnover. The gross margin rose from €486,141 in 2013 to €530,936 in 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about MontiNefro

What is the company number of MontiNefro?
The company number of MontiNefro is 0501.826.728. The VAT number is the same number with BE in front: BE 0501.826.728.
Where is MontiNefro based?
The registered office is at Gagelstraat 3, 8200 Bruges.Company details
What does MontiNefro do?
According to the KBO register, the main activity is specialist medical practice (NACE 86220).
What is the legal form of MontiNefro?
MontiNefro is a private limited company (BV).
When was MontiNefro founded?
MontiNefro was founded on 07-12-2012.
Is MontiNefro still active?
Yes, MontiNefro is an active enterprise in the KBO register.
What is the turnover of MontiNefro?
The turnover in financial year 2025 is ≈ €800,000. This figure is estimated from the gross margin of €530,936 and 31 comparable companies (NACE 86220). It probably lies between €710,000 and €1.1m.Financials
Is MontiNefro profitable?
In financial year 2025, MontiNefro made a profit of €372,932.
Where can I find the annual accounts of MontiNefro?
MontiNefro filed 13 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of MontiNefro due?
MontiNefro must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.